J. Goldman & Co’s Pacira BioSciences PCRX Stock Holding History

J. Goldman & Co’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-121,700	Closed	-$3.02M	–	595
2025 Q1	$3.02M	Sell	121,700 -13,300	-10%	-$318K	0.07%	256
2024 Q4	$2.54M	Buy	+135,000	New	+$2.37M	0.07%	254
2023 Q3	–	Sell	-67,400	Closed	-$2.7M	–	455
2023 Q2	$2.7M	Buy	+67,400	New	+$2.79M	0.1%	188
2019 Q4	–	Sell	-40,000	Closed	-$1.52M	–	323
2019 Q3	$1.52M	Buy	+40,000	New	+$1.6M	0.11%	168
2017 Q4	–	Sell	-30,000	Closed	-$1.13M	–	411
2017 Q3	$1.13M	Buy	+30,000	New	+$1.21M	0.06%	232

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's PCRX Position: Q1 2026 in Review

J. Goldman & Co reduced its Pacira BioSciences (PCRX) stake by 78% in Q1 2026, selling an estimated $7.54M and leaving 97,772 shares worth $2.21M. The position accounts for 0.06% of the portfolio, ranked #307.

J. Goldman & Co first reported a position in PCRX in Q3 2017 and has held it in 11 quarters since. The position peaked at $21.3M in Q1 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

J. Goldman & Co held 97,772 shares of Pacira BioSciences worth $2.21M as of Q1 2026.
J. Goldman & Co sold 339,481 Pacira BioSciences shares in Q1 2026, an estimated $7.54M.
Pacira BioSciences made up 0.06% of J. Goldman & Co's portfolio in Q1 2026, its #307 holding.
J. Goldman & Co first reported a position in Pacira BioSciences in Q3 2017 and has held it in 11 quarters since.
J. Goldman & Co's Pacira BioSciences position peaked at $21.3M in Q1 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.